Business ❯Pharmaceuticals ❯Vaccine Development ❯Cancer Vaccine
Moderna's potential cancer vaccine and AT&T's deal with Rivian boost shares, while Apellis faces regulatory hurdles and Adobe's profit forecast disappoints investors.